Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic Exclusivity? Who Cares! Industry Offers Few Opinions On Potential Changes

This article was originally published in PharmAsia News

Executive Summary

U.S. FDA officials still looking for input after transparency issue not widely addressed during GDUFA policy meeting.

You may also be interested in...



FDA Considers Providing Mid-Review Update For First Generics

“We might as well talk to an answering machine,” sponsor complains at GDUFA public meeting.

Please Complain: FDA Needs GDUFA Meeting Comments, Presenters

Agency officials indicate feedback is critical as generic drug user fee program enters its third year and applications go on the clock in earnest.

Generic Exclusivity Awards Process Might Go Public

FDA wants to know whether 180-day exclusivity should be revealed up front; question is one of many on ANDA reviews to be considered at September public hearing.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC086043

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel